Dr. Macaulay A. Onuigbo
Mayo Clinic
USA
Email: onuigbo.Macaulay@mayo.edu
Qualifications
West African School Certificate, Government College, 1971~1975;
MB BS, Faculty of Medical Sciences, Enugu Campus, University of Nigeria, 1981;
Master of Science, Medical Biochemistry, College of Medicine of the University of Nigeria, University of Nigeria, 1986~1988;
Clinical Fellowship, Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, 2000~2002;
MBA, University of Wisconsin Consortium, University of Wisconsin, 2009
Selected Publications
Onuigbo MA, Skalski J. Newly symptomatic central diabetes insipidus in ESRD with adult polycystic kidney disease following intracranial hemorrhage: the first reported case. Med Sci Monit 2010 Feb 26; 16(3):CS29-32. PMID:20190689.
Onuigbo M, Frenandes R, Nijhawan V. The ASTRAL trial results revisited--to stent or not to stent in renal artery stenosis? QJM 2010 May; 103(5):357. Epub 2010 Jan 21. PMID:20093328. DOI:10.1093/qjmed/hcp202.
Onuigbo MA, Nesbit A, Weisenbeck J, Hurlburt J. Hepatitis B surface antigenemia following recombinant Engerix B hepatitis B vaccine in an 81-year-old ESRD patient on hemodialysis. Ren Fail 2010 May; 32(4):531-2. PMID:20446799. DOI:10.3109/08860221003637369.
Onuigbo MA. Relation between kidney function, proteinuria, and adverse outcomes--a critical look at the application of medical statistics in the Nephrology literature. QJM 2010 Jul; 103(7):537-8. Epub 2010 Apr 11. PMID:20385569. DOI:10.1093/qjmed/hcq053.
Onuigbo MA. Nephrotoxic effects of water-soluble B-vitamin therapy in diabetic nephropathy?--How true can this be? QJM 2010 Jul 14. [Epub ahead of print] PMID:20630906. DOI:10.1093/qjmed/hcq120.
Onuigbo MA. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far? Int J Clin Pract 2010 Sep; 64(10):1341-6. PMID:20716141. DOI:10.1111/j.1742-1241.2010.02448.x.
Onuigbo MA, Lawrence K, Onuigbo NT. Non-dilated obstructive uropathy - an unrecognized cause of acute renal failure in hospitalized US patients: three case reports seen over 6 months in a northwestern Wisconsin Nephrology practice. Ren Fail 2010; 32(10):1226-9. PMID:20954986. DOI:10.3109/0886022X.2010.517343.
Onuigbo MA. Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD. Ren Fail 2010; 32(8):954-8. PMID:20722563. DOI:10.3109/0886022X.2010.502608.
Onuigbo MA. Bilateral lower extremity sequential compression devices (SCDs): a novel approach to the management of intra-dialytic hypotension in the outpatient setting--report of a case series. Ren Fail 2010 Jan; 32(1):32-5. PMID:20113263. DOI:10.3109/08860220903367478.
Onuigbo M. A Downside to Angiotensin Blockade? Renal and Urology News 2009 Jun 18.
Onuigbo MA. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice. Hemodial Int 2009 Oct; 13 Suppl 1:S24-9. PMID:19775421. DOI:10.1111/j.1542-4758.2009.00416.x.
Onuigbo M, Nijhawan V, Fernandes R. The ASTRAL Trial results revisited - To stent or not to stent in Renal Artery Stenosis? [Editorial Commentary] QJM 2009 December [In Print].
Onuigbo MA, Nye D, Iloanya PC. Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. Adv Perit Dial 2009; 25:89-91. PMID:19886325.
Onuigbo MAC, Onuigbo NTC. Chapter 1: Angiotensin Converting Enzyme Inhibitors. In: DeBrue, AN. Angiotensin Converting Enzyme Inhibitors New York: Nova Biomedical Books. Published by Nova Science Publishers; 2009. p. 1-41. (Book chapter)
Onuigbo MA. The natural history of chronic kidney disease revisited--a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: a call for circumspection. Adv Perit Dial 2009; 25:85-8. PMID:19886324.
Onuigbo MA. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution. Nephron Clin Pract 2009; 113(2):c63-9, discussion c70. Epub 2009 Jul 14. PMID:19602900. DOI:10.1159/000228536.
Onuigbo MAC. Reno-prevention vs. reno-protection: A critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET - A call for more circumspection. An International Journal of Medicine S African local excerpted Edition 2009; 8(3).
Onuigbo MAC. Symptomatic uraemia from bilateral obstructive uropathy secondary to metastatic urinary bladder cancer showing only unilateral hydronephrosis: A case report. NDT Plus 2009; 2(5):387-9.
Onuigbo MA. Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET--a call for more circumspection. QJM 2009 Mar; 102(3):155-67. Epub 2008 Dec 19. PMID:19098074. DOI:10.1093/qjmed/hcn142.
Onuigbo MA, Onuigbo NT. Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: an extended Mayo Clinic prospective 63-month experience. Ren Fail 2008; 30(4):363-71. PMID:18569908. DOI:10.1080/08860220801947363.
Onuigbo MA, Onuigbo NT. Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors. Ren Fail 2008; 30(1):73-80. PMID:18197547. DOI:10.1080/08860220701742161.
Onuigbo MA, Onuigbo NT. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study. Ren Fail 2008; 30(1):67-72. PMID:18197546. DOI:10.1080/08860220701742153.
Onuigbo MA, Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40(1):233-9. Epub 2008 Jan 15. PMID:18196471. DOI:10.1007/s11255-007-9299-2.
Onuigbo MA, Onuigbo NT. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. QJM 2008 Jul; 101(7):519-27. Epub 2008 Mar 28. PMID:18375475. DOI:10.1093/qjmed/hcn039.
Onuigbo MA, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience. Med Sci Monit 2005 Oct; 11(10):CR462-9. Epub 2005 Sep 26. PMID:16192897.
Onuigbo M, Weir M. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes Obesity and Metabolism 2003; 5:13-26.